 LONDON, April 10, 2021 GLOBE NEWSWIRE -- Achilles Therapeutics plc NASDAQ: ACHL, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a patient case study from the Companys ongoing Phase IIIa THETIS trial in metastatic or recurrent melanoma at the American Association for Cancer Research AACR Annual Meeting 2021. Through a comprehensive translational research program, data from Patient T-05 offer insight into the in vivo dynamics of clonal neoantigen T cells cNeT post-dosing and the potential to develop a potency-based release assay. 